Finance

Lists
Q3 2026 earnings • in 2 days
See details
ZTS:NYSE
Zoetis Inc
$83.18
+4.34%
(+3.46) 1D
$83.18
0.00% (0.00)
After hours
Closed: Nov 2, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
$80.15
High
$83.22
Low
$79.89
Mkt. cap
34.37B
Avg. vol.
3.90M
Volume
5.42M
Dividend
2.55%
Quarterly dividend
$0.53
Ex-dividend date
Oct 30, 2026
P/E ratio
13.68
52-wk high
$144.83
52-wk low
$68.77
EPS
$6.08
Beta
0.74
Shares outstanding
413.22M
No. of employees
14K
Open
$80.15
High
$83.22
Low
$79.89
Mkt. cap
34.37B
Avg. vol.
3.90M
Volume
5.42M
Dividend
2.55%
Quarterly dividend
$0.53
Ex-dividend date
Oct 30, 2026
P/E ratio
13.68
52-wk high
$144.83
52-wk low
$68.77
EPS
$6.08
Beta
0.74
Shares outstanding
413.22M
No. of employees
14K
News stories
From web sources and news partners
Profile
Zoetis Inc., headquartered in Parsippany, New Jersey, is the largest producer of medicine and vaccinations for pets and livestock worldwide. The company's products include antiparasitics, vaccines, products that relieve itch, anti-infectives, products that alleviate pain, animal health diagnostics, as well as hormones, cardiopulmonary, topical and oral hygiene therapeutics, central nervous system drugs, diuretics, antiemetic, euthanasia, and hepato-digestive products. The company has operations in over 50 countries. In 2025, 70% of the company's revenue came from products for pets and 29% of the company's revenues came from products for livestock. In 2025, 54% of the company's revenue came from customers in the United States. Of this revenue, 79% came from products for dogs and cats, 13% came from products for cattle, and 4% came from products for horses. In 2025, 46% of the company's revenue came from international customers. Of this revenue, 53% came from products for dogs and cats, 19% came from products for cattle, 9% came from products for swine, 7% came from products for poultry, and 3% came from products for horses. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14.5K
Founded1952
HeadquartersParsippany-Troy Hills, New Jersey, United States
SectorPharmaceutical industry
Websitezoetis.com
Analyst ratings
Based on 12 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
4
Hold
8
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current $83.18
$115.00 (+38.25%)
Average
$88.22 (+6.06%)
Lowest
$74.00 (-11.04%)
Analyst
Recommendation
Action
Price target
Projected
Date
Erin Wright
Morgan Stanley
Buy
Maintained
$82.00
-1.4%
10/30/2026
Andrea Alfonso
UBS
Hold
Reiterated
$85.00
+2.2%
10/27/2026
Keith Devas
Jefferies
Hold
Downgraded
$83.00
-0.2%
10/20/2026
Chris Schott
J.P. Morgan
Buy
Maintained
$115.00
+38.3%
10/16/2026
Matthew Dellatorre
Goldman Sachs
Hold
Initiated
$74.00
-11%
10/16/2026
Daniel Clark
Leerink Partners
Hold
Reiterated
-
-
10/01/2026
Jonathan Block
Stifel Nicolaus
Hold
Reiterated
-
-
09/18/2026
Steve Scala
TD Cowen
Buy
Reiterated
$94.00
+13%
08/25/2026
Glen Santangelo
Barclays
Hold
Reiterated
$85.00
+2.2%
08/17/2026
Daniel Grosslight
Citi
Buy
Maintained
$96.00
+15.4%
08/11/2026
David Westenberg
Piper Sandler
Hold
Maintained
$80.00
-3.8%
08/10/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
$95.00
+14.2%
07/06/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
05/08/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
$131.00
+57.5%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
$160.00
+92.4%
02/26/2026
Next call in 2 days
Thu, Nov 5, 8:30 AM
Fiscal period
Q3 2026
- / $1.51
Revenue / Est. (USD)
- / 2.30B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.40B
2.39B
2.26B
2.47B
Cost of goods sold
682.00M
711.00M
640.00M
670.00M
Cost of revenue
682.00M
711.00M
640.00M
670.00M
Research and development expenses
170.00M
199.00M
180.00M
173.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
572.00M
618.00M
584.00M
589.00M
Operating expense
774.00M
848.00M
795.00M
793.00M
Total operating expenses
1.46B
1.56B
1.44B
1.46B
Operating income
944.00M
828.00M
827.00M
1.00B
Other non operating income
-
-6.00M
-1.00M
-2.00M
EBT including unusual items
887.00M
761.00M
758.00M
866.00M
EBT excluding unusual items
899.00M
780.00M
779.00M
948.00M
Income tax expense
166.00M
158.00M
157.00M
175.00M
Effective tax rate
18.71%
20.76%
20.71%
20.21%
Other operating expenses
-
-
-
-
Net income
721.00M
603.00M
601.00M
691.00M
Net profit margin
30.04%
25.26%
26.57%
28.00%
Earnings per share
1.70
1.48
1.53
1.87
Interest and investment income
26.00M
25.00M
21.00M
16.00M
Interest expense
-58.00M
-57.00M
-62.00M
-61.00M
Net interest expenses
-32.00M
-32.00M
-41.00M
-45.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.07B
903.00M
946.00M
1.12B
Gain or loss from assets sale
-
-
-6.00M
-1.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps